Keywords: celltech, cdp571, presented, american, society, rheumatology, meeting

...And With Celltech's CDP571

Article | 31 October 1994

• Print This

Also presented at the American Society of Rheumatology meeting in Minneapolis were Phase II results of Celltech's humanized anti-TNF antibody CDP571. In this study, 36 patients disabled by rheumatoid arthritis, who had already failed to respond to at least one disease-modifying agent, were treated with one of three doses of CDP571 or placebo at Middlesex and Guy's Hospital in London, UK.

Following an injection of the highest dose of antibody (10mg/kg), a reduction of five to six tender joints was seen, corresponding to a 22%-27% reduction, compared to placebo. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.